Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells
Ellen Weisberg(Dana-Farber Cancer Institute), Nathanael S. Gray(Stanford University)
Cited by 42
Related Papers
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
|Nature Chemical Biology|2016|368
Development of Selective Covalent Janus Kinase 3 Inhibitors
|Journal of Medicinal Chemistry|2015|115
Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216
|Journal of Medicinal Chemistry|2021|55